print small

Participating Countries:

Australia

Austria

Belgium

Bulgaria

Canada

Cyprus

Czech Republic

Denmark

European Commission

France

Germany

Greece

Hungary

Ireland

Israel

Italy

Norway

Poland

Portugal

Romania

Russian Federation

Serbia

Slovakia

Slovenia

Spain

Sweden

Switzerland

Turkey

Ukraine

United Kingdom

United States of America

COST is supported by the EU Framework Programme Horizon 2020
This website is supported by COST

Welcome to cost-radiomag.eu

Multifunctional Nanoparticles for Magnetic Hyperthermia and Indirect Radiation Therapy (RADIOMAG)

The Action aims to bring together and to organise the research outcomes from the different participating network members in a practical way to provide clinicians with the necessary input to trial a novel anti-cancer treatment combining magnetic hyperthermia (MH) and radiotherapy, also identifying future research objectives upon appraisal of the obtained results. Feedback between the different working groups here is essential, and is expected that the lifetime of this Action proposal will eventually result in a compendium of best practices for magnetic hyperthermia.

RADIOMAG will generate new and strengthen the existing synergies between technical advances (thermal imaging / MH), new treatment concepts (combined targeting radiosensitisation and magnetic thermotherapy) and biocompatible coating in order to achieve a breakthrough in the clinical application of magnetic hyperthermia. Due to the complexity of this aim, synergies can only be achieved on a longer time frame, by means of workshops, STSMs, joint publications, common Horizon 2020 research proposals and exchange with other COST Actions.

Founding Members

Project Office

STSM



Subscribe to newsletter